CHICAGO TRUST Co NA Purchases Shares of 570 United Therapeutics Co. (NASDAQ:UTHR)

CHICAGO TRUST Co NA acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 570 shares of the biotechnology company’s stock, valued at approximately $204,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. ClariVest Asset Management LLC grew its holdings in United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 42 shares in the last quarter. V Square Quantitative Management LLC acquired a new position in shares of United Therapeutics in the second quarter valued at about $30,000. Rise Advisors LLC bought a new position in United Therapeutics during the first quarter worth about $32,000. Innealta Capital LLC acquired a new stake in United Therapeutics in the 2nd quarter worth about $33,000. Finally, USA Financial Formulas bought a new stake in United Therapeutics in the 3rd quarter valued at about $33,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Price Performance

Shares of UTHR opened at $357.10 on Tuesday. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. The stock has a market cap of $15.89 billion, a PE ratio of 16.41, a PEG ratio of 1.29 and a beta of 0.57. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $366.08. The business has a 50-day simple moving average of $347.35 and a two-hundred day simple moving average of $305.10.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The business had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. During the same quarter last year, the business earned $5.24 EPS. The firm’s quarterly revenue was up 19.8% compared to the same quarter last year. Analysts anticipate that United Therapeutics Co. will post 24.71 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price target for the company from $310.00 to $321.00 in a research note on Thursday, July 11th. Oppenheimer raised their price target on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th. UBS Group upped their price objective on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research report on Monday, July 8th. Wells Fargo & Company raised their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $400.00 price target on shares of United Therapeutics in a report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $357.17.

Insider Activity

In related news, CFO James Edgemond sold 7,794 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $355.54, for a total value of $2,771,078.76. Following the completion of the sale, the chief financial officer now directly owns 5,344 shares in the company, valued at $1,900,005.76. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Monday, July 22nd. The shares were sold at an average price of $331.32, for a total value of $1,192,752.00. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $43,071.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James Edgemond sold 7,794 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $355.54, for a total transaction of $2,771,078.76. Following the sale, the chief financial officer now owns 5,344 shares of the company’s stock, valued at approximately $1,900,005.76. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 101,638 shares of company stock valued at $34,431,585. Insiders own 11.90% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.